| Q53099028 | Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. |
| Q38018908 | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors |
| Q42870871 | Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10‐year experience at single institution |
| Q89940664 | Allogeneic hematopoietic stem-cell transplantation for myelofibrosis |
| Q38174781 | Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? |
| Q38569146 | Current Challenges in Stem Cell Transplantation in Myelofibrosis |
| Q33400683 | Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis |
| Q41519713 | Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis |
| Q33643387 | Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis |
| Q38098957 | Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies |
| Q58910044 | Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation |
| Q38095967 | Myelofibrosis 2012: it's complicated |
| Q39027845 | Myelofibrosis: to transplant or not to transplant? |
| Q48069751 | Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation |
| Q54980872 | Recent advances in the diagnosis and management of primary myelofibrosis. |
| Q37738536 | Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis |
| Q37457111 | Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. |
| Q34625390 | Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease |
| Q84065231 | The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries |